119 related articles for article (PubMed ID: 10773855)
1. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials.
Tan IL; Lycklama à Nijeholt GJ; Polman CH; Adèr HJ; Barkhof F
Mult Scler; 2000 Apr; 6(2):99-104. PubMed ID: 10773855
[TBL] [Abstract][Full Text] [Related]
2. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.
Wolinsky JS; Narayana PA; Noseworthy JH; Lublin FD; Whitaker JN; Linde A; Gjörstrup P; Sullivan HC
Neurology; 2000 May; 54(9):1734-41. PubMed ID: 10802777
[TBL] [Abstract][Full Text] [Related]
3. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.
Noseworthy JH; Wolinsky JS; Lublin FD; Whitaker JN; Linde A; Gjorstrup P; Sullivan HC
Neurology; 2000 May; 54(9):1726-33. PubMed ID: 10802775
[TBL] [Abstract][Full Text] [Related]
4. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis DM; Meiner Z; Lehmann D; Gomori JM; Schwarz A; Linde A; Abramsky O
Neurology; 1996 Aug; 47(2):341-6. PubMed ID: 8757002
[TBL] [Abstract][Full Text] [Related]
5. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Neurology; 1996 Oct; 47(4):895-900. PubMed ID: 8857715
[TBL] [Abstract][Full Text] [Related]
6. Lessons from linomide: a failed trial, but not a failure.
Schwid SR; Trotter JL
Neurology; 2000 May; 54(9):1716-7. PubMed ID: 10802772
[No Abstract] [Full Text] [Related]
7. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.
Whitaker JN; Wolinsky JS; Narayana PA; Bartolucci AA; Noseworthy JH; Lublin FD; Linde A; Gjörstrup P; Sullivan HC;
Arch Neurol; 2001 Jan; 58(1):49-54. PubMed ID: 11176936
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation with linomide: possible novel therapy for multiple sclerosis.
Abramsky O; Lehmann D; Karussis D
Mult Scler; 1996 Nov; 2(4):206-10. PubMed ID: 9345375
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
12. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
13. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
14. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
15. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Mult Scler; 1996 Jul; 1(6):348. PubMed ID: 9345415
[No Abstract] [Full Text] [Related]
16. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Vollmer TL; Wynn DR; Alam MS; Valdes J
Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
[TBL] [Abstract][Full Text] [Related]
17. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
Lebrun C
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
[TBL] [Abstract][Full Text] [Related]
18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells.
Lehmann D; Karussis D; Mizrachi-Koll R; Linde AS; Abramsky O
Clin Immunol Immunopathol; 1997 Nov; 85(2):202-9. PubMed ID: 9344704
[TBL] [Abstract][Full Text] [Related]
20. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
